Bayer said the recent judgment by an FDA advisory panel confirms the safety of the company's painkiller Aleve, distinguishing the safety profile of the drug's major ingredient, naproxen, from selective Cox-2 inhibitors and nonselective and nonsteroidal anti-inflammatory drugs. The company also noted an Alzheimer's trial was halted last December because of "administrative and practical" issues and not because of Aleve.

Full Story:

Related Summaries